1 Globally, there were 1.09 million new cases diagnosed with gastric cancer, and 769,000 deaths occurred due to gastric cancer. Gastric cancer, also known as stomach cancer, is the sixth most frequent malignancy and the fourth leading cause of death in the world. Keywords: gastric cancer, melatonin, growth, angiogenesis, vascular endothelial growth factor, angiogenin, chick embryo tumor xenograft model Further studies are needed to investigate the therapeutic potential of MLT for gastric cancer as compared to drugs clinically approved. ELISA showed that MLT at concentrations of 0.0041, 0.012, 0.037 and 0.11 had no remarkable impact on VEGF and angiopoietin secretion, while MLT at 1 mM significantly suppressed VEGF and angiopoietin production in chick embryo tumor xenograft models with SGC-7901 cells ( P = 0.023).Ĭonclusion: Our data demonstrate that MLT inhibits gastric cancer growth in vitro at a concentration-dependent manner, and suppresses angiogenesis of the chick embryo tumor xenograft model with SGC-7901 cells through inhibiting VEGF and angiogenin secretion.

Results: MLT treatment inhibited the growth of SGC-7901 cells at a concentration-dependent manner, and treatment with MLT at 1 mM was found to markedly reduce the volume and weight of tumors bearing the allantois of chicken embryos. In addition, the VEGF and angiogenin secretion was measured in the supernatant of chick embryo tumor xenograft models with ELISA. Materials and Methods: The growth of gastric cancer SGC-7901 cells was measured using MTT assay, and a chick embryo tumor xenograft model was generated to observe the effect of melatonin on gastric cancer growth in vivo. This study aimed to investigate the activity of melatonin against gastric cancer growth in a chick embryo tumor xenograft model and explore the possible mechanisms. Purpose: Previous studies have shown the antitumor activity of melatonin against a wide range of human cancers however, the impact of melatonin on gastric cancer growth remains to be illustrated.

Rixiong Wang, 1, 2 Hui Liu, 3, 4 Jun Song, 3, 4 Qing Wu 1, 2ġDepartment of Oncology, the First Affiliated Hospital of Fujian Medical University, Fuzhou City, People’s Republic of China 2Fujian Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital of Fujian Medical University, Fuzhou City, People’s Republic of China 3Department of Human Anatomy, Histology and Embryology, Fujian Medical University, Fuzhou City, People’s Republic of China 4Key Laboratory of the Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou City, People’s Republic of ChinaĬorrespondence: Rixiong Wang Email

Spss 16.0 (spss inc., chicago, il, usa